(INSM) Insmed - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 35.012m USD | Total Return: 139.4% in 12m

Rare Disease Therapies, Lung Disease Treatments, Gene Therapy
Total Rating 41
Safety 30
Buy Signal 0.45
Biotechnology
Industry Rotation: +3.7
Market Cap: 35.0B
Avg Turnover: 302M USD
ATR: 4.04%
Peers RS (IBD): 52.8
Risk 5d forecast
Volatility46.2%
Rel. Tail Risk-10.4%
Reward TTM
Sharpe Ratio1.81
Alpha113.47
Character TTM
Beta0.230
Beta Downside2.506
Drawdowns 3y
Max DD35.67%
CAGR/Max DD3.21
EPS (Earnings per Share) EPS (Earnings per Share) of INSM over the last years for every Quarter: "2021-03": -0.89, "2021-06": -0.91, "2021-09": -0.89, "2021-12": -0.95, "2022-03": -0.8, "2022-06": -0.8, "2022-09": -1.09, "2022-12": -1.21, "2023-03": -1.17, "2023-06": -1.78, "2023-09": -1.11, "2023-12": -1.28, "2024-03": -1.06, "2024-06": -1.94, "2024-09": -1.27, "2024-12": -1.32, "2025-03": -1.42, "2025-06": -1.7, "2025-09": -1.75, "2025-12": -1.54, "2026-03": 0,
EPS CAGR: 13.94%
EPS Trend: 3.3%
Last SUE: 3.52
Qual. Beats: 1
Revenue Revenue of INSM over the last years for every Quarter: 2021-03: 40.214, 2021-06: 45.366, 2021-09: 46.757, 2021-12: 56.124, 2022-03: 53.107, 2022-06: 65.221, 2022-09: 67.73, 2022-12: 59.3, 2023-03: 65.214, 2023-06: 77.229, 2023-09: 79.072, 2023-12: 83.693, 2024-03: 75.5, 2024-06: 90.34, 2024-09: 93.425, 2024-12: 104.442, 2025-03: 92.823, 2025-06: 107.415, 2025-09: 142.342, 2025-12: 263.843, 2026-03: null,
Rev. CAGR: 53.34%
Rev. Trend: 89.1%
Last SUE: 0.10
Qual. Beats: 0

Warnings

Share dilution 19.3% YoY - potential capital distress

Interest Coverage Ratio -14.2 is critical

Altman Z'' -11.89 < 1.0 - financial distress zone

Tailwinds

No distinct edge detected

Description: INSM Insmed

Insmed Inc. is a biotechnology company focused on therapies for serious and rare diseases.

Their primary commercial product, ARIKAYCE, treats refractory nontuberculous mycobacterial lung infections. This product addresses a niche market within infectious diseases.

The company has several drug candidates in clinical trials, including brensocatib for bronchiectasis and treprostinil palmitil inhalation powder for pulmonary hypertension. Developing new drugs is a core activity in the biotechnology sector.

Insmed also has early-stage programs in gene therapy. Further research on ValueRay can provide detailed insights into their clinical pipeline and market potential.

Headlines to Watch Out For
  • ARIKAYCE sales growth drives revenue
  • Brensocatib clinical trial results impact future sales
  • Treprostinil palmitil inhalation powder development costs
  • Gene therapy pipeline success influences valuation
Piotroski VR‑10 (Strict) 1.5
Net Income: -1.28b TTM > 0 and > 6% of Revenue
FCF/TA: -0.44 > 0.02 and ΔFCF/TA -9.20 > 1.0
NWC/Revenue: 218.5% < 20% (prev 364.1%; Δ -145.5% < -1%)
CFO/TA -0.41 > 3% & CFO -935.0m > Net Income -1.28b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.83 > 1.5 & < 3
Outstanding Shares: last quarter (213.6m) vs 12m ago 19.34% < -2%
Gross Margin: 79.41% > 18% (prev 0.76%; Δ 7.86k% > 0.5%)
Asset Turnover: 28.27% > 50% (prev 17.96%; Δ 10.31% > 0%)
Interest Coverage Ratio: -14.23 > 6 (EBITDA TTM -1.18b / Interest Expense TTM 83.8m)
Altman Z'' -11.89
A: 0.59 (Total Current Assets 1.79b - Total Current Liabilities 468.9m) / Total Assets 2.26b
B: -2.49 (Retained Earnings -5.64b / Total Assets 2.26b)
C: -0.56 (EBIT TTM -1.19b / Avg Total Assets 2.14b)
D: -3.69 (Book Value of Equity -5.63b / Total Liabilities 1.53b)
Altman-Z'' Score: -11.89 = D
Beneish M -2.21
DSRI: 1.62 (Receivables 140.9m/52.0m, Revenue 606.4m/363.7m)
GMI: 0.96 (GM 79.41% / 76.43%)
AQI: 1.03 (AQ_t 0.15 / AQ_t-1 0.14)
SGI: 1.67 (Revenue 606.4m / 363.7m)
TATA: -0.15 (NI -1.28b - CFO -935.0m) / TA 2.26b)
Beneish M-Score: -2.21 (Cap -4..+1) = BB
What is the price of INSM shares? As of April 08, 2026, the stock is trading at USD 163.03 with a total of 1,348,477 shares traded.
Over the past week, the price has changed by -0.30%, over one month by +13.90%, over three months by -7.37% and over the past year by +139.43%.
Is INSM a buy, sell or hold? Insmed has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy INSM.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the INSM price?
Analysts Target Price 214.3 31.5%
Insmed (INSM) - Fundamental Data Overview as of 06 April 2026
P/E Forward = 16.3666
P/S = 57.7354
P/B = 47.4055
P/EG = 1.0916
Revenue TTM = 606.4m USD
EBIT TTM = -1.19b USD
EBITDA TTM = -1.18b USD
Long Term Debt = 541.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 768.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -661.9m USD (recalculated: Debt 768.2m - CCE 1.43b)
Enterprise Value = 34.35b USD (35.01b + Debt 768.2m - CCE 1.43b)
Interest Coverage Ratio = -14.23 (Ebit TTM -1.19b / Interest Expense TTM 83.8m)
EV/FCF = -34.43x (Enterprise Value 34.35b / FCF TTM -997.6m)
FCF Yield = -2.90% (FCF TTM -997.6m / Enterprise Value 34.35b)
 FCF Margin = -164.5% (FCF TTM -997.6m / Revenue TTM 606.4m)
 Net Margin = -210.5% (Net Income TTM -1.28b / Revenue TTM 606.4m)
 Gross Margin = 79.41% ((Revenue TTM 606.4m - Cost of Revenue TTM 124.9m) / Revenue TTM)
Gross Margin QoQ = 82.51% (prev 79.37%)
Tobins Q-Ratio = 15.17 (Enterprise Value 34.35b / Total Assets 2.26b)
Interest Expense / Debt = 2.68% (Interest Expense 20.6m / Debt 768.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -942.3m (EBIT -1.19b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.83 (Total Current Assets 1.79b / Total Current Liabilities 468.9m)
Debt / Equity = 1.04 (Debt 768.2m / totalStockholderEquity, last quarter 739.0m)
 Debt / EBITDA = 0.56 (negative EBITDA) (Net Debt -661.9m / EBITDA -1.18b)
 Debt / FCF = 0.66 (negative FCF - burning cash) (Net Debt -661.9m / FCF TTM -997.6m)
 Total Stockholder Equity = 758.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.53% (Net Income -1.28b / Total Assets 2.26b)
RoE = -168.4% (Net Income TTM -1.28b / Total Stockholder Equity 758.4m)
RoCE = -91.80% (EBIT -1.19b / Capital Employed (Equity 758.4m + L.T.Debt 541.0m))
 RoIC = -65.46% (negative operating profit) (NOPAT -942.3m / Invested Capital 1.44b)
 WACC = 6.69% (E(35.01b)/V(35.78b) * Re(6.79%) + D(768.2m)/V(35.78b) * Rd(2.68%) * (1-Tc(0.21)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 21.46%
 [DCF] Fair Price = unknown (Cash Flow -997.6m)
 EPS Correlation: 3.30 | EPS CAGR: 13.94% | SUE: 3.52 | # QB: 1
Revenue Correlation: 89.05 | Revenue CAGR: 53.34% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.81 | Chg7d=+0.027 | Chg30d=+0.060 | Revisions Net=+2 | Analysts=13
EPS current Year (2026-12-31): EPS=-2.81 | Chg7d=+0.039 | Chg30d=+0.133 | Revisions Net=+0 | Growth EPS=+56.2% | Growth Revenue=+180.7%
EPS next Year (2027-12-31): EPS=0.67 | Chg7d=+0.269 | Chg30d=+0.427 | Revisions Net=-1 | Growth EPS=+123.8% | Growth Revenue=+65.0%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle